NASDAQ:IMGNImmunoGen Stock Price, Forecast & News

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMGN stock has increased by 14.2% and is now trading at $3.85.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ImmunoGen.

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for ImmunoGen.

ImmunoGen, Inc. (NASDAQ:IMGN) posted its earnings results on Friday, July, 31st. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.04. The biotechnology company had revenue of $15.03 million for the quarter, compared to analysts' expectations of $14.29 million.
View ImmunoGen's earnings history.

ImmunoGen issued an update on its FY 2020 Pre-Market earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $63.12 million.

4 Wall Street analysts have issued twelve-month target prices for ImmunoGen's shares. Their forecasts range from $9.00 to $12.00. On average, they expect ImmunoGen's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 172.7% from the stock's current price.
View analysts' price targets for ImmunoGen.

News coverage about IMGN stock has trended negative this week, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ImmunoGen earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about ImmunoGen.

ImmunoGen saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 12,990,000 shares, a drop of 23.5% from the March 31st total of 16,990,000 shares. Based on an average daily trading volume, of 3,620,000 shares, the days-to-cover ratio is presently 3.6 days.
View ImmunoGen's Short Interest.

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Pfizer (PFE), Immunomedics (IMMU), Micron Technology (MU), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer LP Unit (ET), NVIDIA (NVDA) and Opko Health (OPK).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Healthcare of Ontario Pension Plan Trust Fund (0.48%), Bank of New York Mellon Corp (0.45%), Swiss National Bank (0.22%), California Public Employees Retirement System (0.22%), Raymond James & Associates (0.18%) and State of Wisconsin Investment Board (0.14%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, David G Foster, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll.
View institutional ownership trends for ImmunoGen.

IMGN stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Healthcare of Ontario Pension Plan Trust Fund, Russell Investments Group Ltd., Alps Advisors Inc., SG Americas Securities LLC, Natixis Advisors L.P., Commonwealth Equity Services LLC, and Virtus ETF Advisers LLC. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, David G Foster, Mark J Enyedy, and Thomas Ryll.
View insider buying and selling activity for ImmunoGen.

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Principal Financial Group Inc., HighTower Advisors LLC, Hussman Strategic Advisors Inc., Rafferty Asset Management LLC, Monarch Partners Asset Management LLC, California Public Employees Retirement System, and Swiss National Bank.
View insider buying and selling activity for ImmunoGen.

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMGN stock can currently be purchased for approximately $3.85.

ImmunoGen has a market capitalization of $671.99 million and generates $82.27 million in revenue each year. The biotechnology company earns $-104,130,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.

The official website for ImmunoGen is www.immunogen.com.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]